• 1
    Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn.). Chest 2008; 133(6 Suppl): 234S56S.
  • 2
    Kessler CM. Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications. Semin Hematol 2004; 41(1 Suppl 1): 4450.
  • 3
    Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 48714879.
  • 4
    Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXA-DVT study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007; 116: 1807.
  • 5
    Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008; 112: 22427.
  • 6
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 276575.
  • 7
    Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97: 9317.
  • 8
    Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 141926.
  • 9
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 94956.
  • 10
    Van Ryn D, Ruehl H, Priepke N, Hauel W, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant factor VIIa or activated prothrombin concentrate complex. Haematologia 2008; 93(Suppl. 1): 148.
  • 11
    Wienen W, Ruehl D, Stassen JM, Priepke H, Ries UJ, Hauel N. Effect of recombinant factor VIIa or activated prothrombin complex concentrate on the bleeding time in anaesthetized rats during anticoagulant treatment with the direct thrombin inhibitor dabigatran. J Thromb Haemost 2008; 3(Suppl. 1): P1703.
  • 12
    Ovanesov MV, Panteleev MA, Sinauridze EI, Kireev DA, Plyushch OP, Kopylov KG, et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 2008; 19: 74355.
  • 13
    Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008; 248: 618.
  • 14
    Vande WJ, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007; 2: 2328.
  • 15
    Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth 2004; 93: 84258.
  • 16
    Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 2009; 123: 68796.
  • 17
    Benz K, Nauck MA, Bohler J, Fischer KG. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use. Clin J Am Soc Nephrol 2007; 2: 4706.
  • 18
    Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 6: 1697706.
  • 19
    Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292303.
  • 20
    Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 87380.